Alector (ALEC) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

ALEC Alector

Watchlist

1.970
-0.070-3.43%

Close Dec 13 16:00 ET

1.970
0.0000.00%

Post 16:20 ET

192.93MMarket Cap-1.15P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Ra Capital Management, L.p. Reports 9.9% Passive Stake in Alector Inc as of Nov 29 - SEC Filing
ReutersDec 6 17:33 ET
BofA Securities Downgrades Alector(ALEC.US) to Sell Rating, Cuts Target Price to $1
Moomoo NewsDec 5 11:35 ET · Ratings
Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.
BenzingaDec 4 14:44 ET
Express News | Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform
BenzingaDec 4 14:44 ET
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
BenzingaDec 4 14:20 ET
BofA Securities Downgrades Alector to Underperform
MT NewswiresDec 4 07:24 ET

Comments

102308472

Dec 4 07:53

$Alector (ALEC.US)$ NO MORE HOPE

Daily Investors

Nov 26 17:00

🤫

Jaguar8

Nov 25 15:06

NEWS

$Alector (ALEC.US)$
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Alector announced disappointing results from its INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's disease. The drug failed to meet its primary endpoint of slowing disease progression and showed no significant effects on secondary endpoints or biomarkers. While AL002 achieved target engagement, it did not demonstrate treatment benefit...

Jaguar8

Sep 19 07:24

NEWS

$Alector (ALEC.US)$
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
Alector (Nasdaq: ALEC) presented baseline characteristics for its pivotal INFRONT-3 Phase 3 clinical trial at the 14th International Conference on Frontotemporal Dementias. The trial evaluates latozinemab, a novel monoclonal antibody, for treating frontotemporal dementia with progranulin gene mutation (FTD-GR...

Jaguar8

Jul 28 07:06

NEWS

$Alector (ALEC.US)$
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of AL002, a TREM2 agonist, at AAIC® 2024.
The trial, involving 381 participants with early Alzheimer's disease (AD), is the first global Phase 2 study evaluating a TREM2 agonist's safety and efficacy in slowing AD progression.
Key point...

Heat List

Overall

No Data